Can Bristol-Myers Squibb continue to write the myth, Opdivo Phase III clinical trial reaches the primary endpoint

On April 8, local time, Bristol Myers Squibb announced that its PD-1 inhibitor Opdivo (nivolumab, nivolumab) has reached its primary endpoint in a phase 3 clinical trial of the first-line combination therapy.
Treat patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC).

Cancer with Chinese characteristics "Esophageal cancer" Esophageal cancer is a common gastrointestinal tumor and the eighth most common cancer in the world.

According to statistics, about 544,000 people will die of esophageal cancer in 2020.

The vast majority of esophageal cancer is divided into the following two subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC).

Among them, esophageal squamous cell carcinoma (esophageal squamous cell carcinoma, ESCC) is the most common type of esophageal cancer in the world.
Since most patients are diagnosed at an advanced stage, the mortality rate is extremely high.
Even in developed countries, the 5-year survival rate It's also very low.

A milestone in immunotherapy, Opdivo, as the world's first PD-1 inhibitor, has a legendary anti-cancer road.

In 1992, Japanese immunologist Motoshusuke discovered programmed death receptor 1 (PD-1) for the first time and pioneered cancer immunotherapy.
His achievements ranked first among the top ten scientific breakthroughs in Science.

In 2018, Professor Shuyou Moto was awarded the Nobel Prize in Physiology or Medicine in recognition of his outstanding contribution to the field of cancer therapy that suppresses negative immune regulation.

In 2014, Opdivo was the first to market in Japan for the treatment of malignant melanoma and became the world's first PD-1 inhibitor approved by regulatory agencies.

In the following 4 years, Opdivo won 17 indications, involving lung cancer (non-small cell lung cancer and small cell lung cancer), melanoma, kidney cancer, Hodgkin’s lymphoma, head and neck squamous cell carcinoma, bladder cancer, and colorectal cancer.
9 tumor types including cancer, liver cancer, and stomach cancer.

In 2018, the drug officially entered the Chinese market and became the first PD-1 anti-cancer drug approved for marketing in mainland China.

So far, there are 5 types of PD-1 antibodies that have been approved for marketing in my country, including Hengrui Medicine’s Carrelizumab, Xinda Pharmaceutical’s Sintilizumab, Junshi Biologics’ Teriprizumab, Keytruda of Merck and Opdivo of Bristol-Myers Squibb.

Opdivo first-line combination therapy Bristol-Myers Squibb Opdivo first-line combination therapy Phase 3 CheckMate -648 trial is mainly to evaluate Opdivo (nivolumab) combined with chemotherapy or Opdivo combined with Yervoy (ipilimumab) for unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) The patient's treatment effect.

Interim data results show that the combination of Opdivo and chemotherapy significantly prolongs the overall survival (OS) of patients.

At the same time, this combination has also brought significant improvement in the progression-free survival (PFS) of patients whose tumors express PD-L1.

At the same time, the results of the study found that the combination of Opdivo and Yervoy can also significantly extend the overall survival of patients.

However, in patients whose tumors express PD-L1, this combination therapy did not reach the primary endpoint of PFS.

Summary PD-1/PD-L1 inhibitors have become a hot spot in the field of innovative tumor drugs due to their broad spectrum and safety.
Since the discovery of this important target for tumor immunotherapy, it has shouldered the responsibility of humans to overcome cancer.
Important mission.

In the future, I hope that the anti-cancer drug Opdivo will bring more surprises to the medical community to benefit more cancer patients.

End References: [1]CORRECTING and REPLACING Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal.
.
.